Why the study?
Does insertable cardiac monitor-based high-risk detection combined with nurse-managed protocolized diuretic interventions improve outcomes in patients with heart failure?
RCT (n=711)
1:1
Does insertable cardiac monitor-based high-risk detection combined with nurse-managed protocolized diuretic interventions improve outcomes in patients with heart failure?
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“A key lesson from the ALLEVIATE-HF trial is that alerts are not treatment, and signals without a timely response lose their clinical impact. Future studies should stop treating the alert as the intervention and instead define the alert-to-action pathway as the true intervention.”
An insertable cardiac monitor-based risk detection strategy with centrally coordinated diuretic intervention was safe but did not significantly improve a hierarchical composite of clinical and patient-reported outcomes in heart failure patients.
BACKGROUND: Early identification of worsening heart failure (HF) may improve outcomes. OBJECTIVES: This study aims to assess if insertable cardiac monitor (ICM)-based high-risk detection combined with centrally managed, nurse-facilitated, individually protocolized diuretic interventions is safe and improves HF outcomes. METHODS: A Reveal LINQ (Medtronic) ICM with an investigational HF risk-status software was implanted in participants with HF who were randomized 1:1 to an intervention arm (high-risk HF alert triggering protocolized diuretic regimen) or an observation arm (standard care). The primary safety endpoint was intervention-related serious adverse events and the primary efficacy endpoint was a 5-component hierarchical composite including cardiovascular death or HF hospitalization or outpatient HF event within 60 days of high-risk onset, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, and 6-minute walk distance, analyzed using win ratio. RESULTS: A total of 711 participants were randomized (357 intervention, 354 observation). The primary composite endpoint did not significantly differ between groups (win ratio: 0.79; 95% CI: 0.62-1.01; P = 0.06). Over a mean follow-up of 17.3 ± 8.9 months, the serious adverse events rate was 0.32% (95% CI: 0.10%-0.99%; prespecified safety threshold ≤5%). The cumulative cardiovascular death and HF events were numerically higher in the intervention group (HR: 1.43; 95% CI: 0.95-2.15; P = 0.091). In an exploratory sensitivity analysis adjusting for a baseline Kansas City Cardiomyopathy Questionnaire imbalance, the win ratio was 1.02 (95% CI: 0.80-1.31; P = 0.85). CONCLUSIONS: ICM-based risk status detection with centrally coordinated diuretic intervention was safe and yielded a neutral result for the primary composite outcome under the tested implementation strategy (ALLEVIATE-HF [Algorithm Using LINQ Sensors for Evaluation and Treatment of Heart Failure]; NCT04452149).
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Butler et al. (2026) conducted an RCT in heart failure (n=711). ICM-based high-risk detection with protocolized diuretic intervention vs. standard care was evaluated on 5-component hierarchical composite including cardiovascular death or HF hospitalization or outpatient HF event within 60 days of high-risk onset, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, and 6-minute walk distance (win ratio 0.79, 95% CI 0.62-1.01, p=0.06).
Synapse has enriched 10 related papers. Consider them for comparative context: